AmCham’s Pharmaceutical Committee has suggestions. Year after year, a key concern of the major pharmaceutical companies operating in Taiwan is the ease with which new drugs and new indications (meaning new applications for existing treatments) can enter the market. Given Taiwan’s single-payer universal healthcare system, much depends on whether the National Health Insurance Administration (NHIA)…

As Taiwan’s population matures into a “super-aged” society, with a predicted 20% of its population 65 years or older by 2025, the problem of long-term care for Taiwan’s elderly population looms. Taiwan’s doctors of chiropractic see themselves as potential contributors to meeting this challenge. Chiropractic, dedicated to the treatment and prevention of disorders of the…

A visiting delegation urges early passage of Patent Linkage legislation. During a recent visit to Taipei, a six-member delegation from the Washington, DC-based Pharmaceutical Research and Manufacturers of America (PhRMA) urged Taiwan’s legislature to give early attention to pending bills to strengthen intellectual property protection for pharmaceuticals. Passage of the proposed amendments to the Pharmaceutical…